On Demand Webinar
Radiotracer and antibody-drug conjugate (ADC) development both demand precision. But how confident can teams be that the molecule is hitting the right target, in the right tumors, at the right time?
This webinar is designed specifically for teams developing ADCs or biologics aiming to make faster, more informed go/no-go decisions. Learn how radiolabeling provides real-time biodistribution data across clinically relevant patient-derived xenograft (PDX) models — revealing precisely where it’s going, how much it reaches the tumor and whether the targeting is genuinely effective.
Key Topics:
- Real-world examples of how radiolabeled ADCs and biologics are being applied in preclinical research today
- Scientific considerations for transitioning from standard ADC payloads to radiolabeled approaches
- How imaging-based targeting validation can align R&D goals with regulatory and clinical expectations
Register Now!
Meet Our Presenters:
Dr. Shankar Vallabhajosula, PhD, Professor of Radiochemistry and Radiopharmacy, Weill Cornell Medical College
Dr. Shankar Vallabhajosula, has over four decades of contributions to nuclear medicine. Earning his PhD in 1980 from USC, he advanced patient care through the development of more than 30 IND radiopharmaceuticals, including an NDA for [18F]FDG. He has published over 130 scientific papers and authored two textbooks on molecular imaging. A past president and CSO of NCM USA, he is currently VP of Radiopharmaceutical Sciences at Convergent Therapeutics. Recognized with the 2007 Berson and Yalow Award and 2022 SNMMI Lifetime Achievement Award, Dr. Vallabhajosula remains a leader in PET and targeted therapy.
Dr. Denis R. Beckford-Vera, PhD, Head of Radiopharmacology, Champions Oncology
Denis Beckford-Vera PhD, is a radiopharmaceutical R&D leader with 20+ years of experience advancing novel imaging agents and targeted radiotherapies from discovery to clinic. He specializes in immunoPET and alpha/beta-emitting therapeutics, with recognized achievements in CD46- and CD33-directed radioimmunotherapies. Denis has built and led high-performing teams, established laboratories, and guided programs through IND-enabling studies and first-in-human trials. He holds a PhD in Nuclear Chemistry, a miniMBA from Rutgers, and executive training from Wharton. He is the author of more than 25 peer-reviewed publications, four book chapters, and two U.S. patents, blending deep scientific expertise with strategic leadership in precision oncology.